A Citigroup analyst initiated coverage on Acadia with a Buy rating and announced a price target of $38. Additionally the US District Court for the District of Delaware has issued a summary judgment in favor of Acadia, affirming the validity of the NUPLAZID (pimavanserin) '740 composition of matter patent on all grounds
A Citigroup analyst initiated coverage on Acadia with a Buy...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.27 |
Change
-1.370(6.33%) |
Mkt cap ! $2.588B | |||
| Open | High | Low | Value | Volume |
| $21.62 | $21.63 | $20.24 | $11.01M | 531.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1111 | $20.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.28 | 338 | 1 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.37 |
Change
-1.370 ( 5.24 %) |
||||
| Open | High | Low | Volume | ||
| $21.61 | $21.62 | $20.25 | 138748 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| NEU (ASX) Chart |